Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AOC 1020
AOC-1020 · 1 trial · 17 indications
Assessment of muscle strength using standardized quantitative measurements
| Arm | Type | Description |
|---|---|---|
| Del-brax | EXPERIMENTAL | Del-brax (AOC 1020) will be administered 13 times |
| Placebo | PLACEBO_COMPARATOR | Saline will be administered 13 times |
| Name | Type | Description |
|---|---|---|
| AOC-1020 | DRUG | Del-brax will be administered by intravenous (IV) infusion. |
| Placebo | DRUG | Placebo will be administered by intravenous (IV) infusion. |
Inclusion Criteria: * Clinical and genetic diagnosis of FSHD1 or FSHD2 * Ability to walk independently at pre-specified walking speed (orthoses and ankle braces allowed) for at least 10 meters at screening * Adequate muscle strength based on QMT composite score Exclusion Criteria: * Breastfeeding...
AOC 1020 is an investigational small molecule being developed for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD), a neurological condition. It is currently in Phase 2 clinical development and has received Fast Track and Orphan Drug designations from the FDA.
AOC 1020 is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol RNA.
AOC 1020 is currently in Phase 2 clinical development. It has completed a Phase 1/2 study and is being evaluated in an ongoing Phase 2 open-label extension study for FSHD. It is not yet approved by the FDA.
AOC 1020 has been studied in clinical trials including NCT05747924, a completed Phase 1/2 study in participants with FSHD, and NCT06547216, an active Phase 2 open-label extension study. These trials have enrolled participants in the United States, Canada, and the United Kingdom.
Yes, AOC 1020 is also referred to as Del-brax. A Phase 3 clinical trial (NCT07038200) is currently recruiting participants to evaluate Del-brax, also known as AOC 1020, in individuals with FSHD.